1800-272-662
Shopping Cart 0
countryflagAU
Login

CSL Ltd

Healthcare US CSLLY

25.31USD
0.10(0.42%)

Last update at 2026-03-11T18:00:00Z

Day Range

25.2425.88
LowHigh

52 Week Range

71.51108.82
LowHigh

Fundamentals

  • Previous Close 25.20
  • Market Cap92686.22M
  • Volume4705
  • P/E Ratio42.45
  • Dividend Yield1.23%
  • EBITDA3876.00M
  • Revenue TTM13310.00M
  • Revenue Per Share TTM13.80
  • Gross Profit TTM 6844.00M
  • Diluted EPS TTM2.26

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 2663.00M 2779.60M 2963.10M 2572.70M 2341.10M
Minority interest -50.00000M - - - 0.00000M
Net income 2194.00M 2254.70M 2375.00M 2102.50M 1918.70M
Selling general administrative 1086.00M 688.00M 731.70M 691.80M 574.80M
Selling and marketing expenses 1454.00M 960.70M 980.20M 896.20M 866.80M
Gross profit 6708.00M 5663.50M 5798.60M 5176.10M 4748.70M
Reconciled depreciation 831.00M 542.50M 495.30M 610.96M 536.03M
Ebit 3071.00M 2922.40M 3198.18M 2723.50M 2517.80M
Ebitda 3902.00M 3464.90M 3629.20M 3143.30M 2893.20M
Depreciation and amortization 831.00M 542.50M 431.02M 419.80M 375.40M
Non operating income net other - - - - 0.00000M
Operating income 4884.05M 4239.47M 4174.17M 3936.21M 3566.70M
Other operating expenses 3989.22M 2951.84M 2322.20M 2037.44M 2049.57M
Interest expense 408.00M 142.80M 170.80M 150.80M 176.70M
Tax provision 419.00M 524.90M 588.10M 685.12M 602.31M
Interest income 38.00M 17.40M 3.90M 10.20M 19.68M
Net interest income -406.00000M -160.60000M -166.90000M -209.52936M -232.28290M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 419.00M 524.90M 588.10M 470.20M 422.40M
Total revenue 13174.00M 10493.10M 10265.30M 9100.50M 8509.90M
Total operating expenses 4606.00M 3347.40M 3208.60M 2929.70M 2648.80M
Cost of revenue 6466.00M 4829.60M 4466.70M 3924.40M 3761.20M
Total other income expense net 136.00M 81.60M 44.70M 50.30M 28.70M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 2244.00M 2254.70M 2375.00M 3063.53M 2735.92M
Net income applicable to common shares 2194.00M 2254.70M 2375.00M 2102.50M 1918.70M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 36234.00M 28346.00M 18156.90M 15464.60M 12314.40M
Intangible assets 8367.00M 1450.80M 1481.60M 986.00M 776.50M
Earning assets - - - - -
Other current assets 9.00M 4.20M 231.80M 180.80M 138.20M
Total liab 18408.00M 13768.50M 9775.60M 8937.20M 7063.10M
Total stockholder equity 15786.00M 14577.50M 8381.30M 6527.40M 5251.30M
Deferred long term liab - - - - 0.00000M
Other current liab 5687.30M 9437.77M 49.70M 3.20M 2.80M
Common stock 517.00M 483.80M 483.80M -4561.00000M -4603.00000M
Capital stock 517.00M 483.80M -4504.60000M -4561.00000M -4603.00000M
Retained earnings 14621.00M 13503.40M 12252.70M 10752.10M 9612.30M
Other liab 2628.00M 1496.50M 1338.90M 1155.90M 632.70M
Good will 8079.00M 1187.30M 1188.10M 1154.20M 1101.80M
Other assets 1177.00M 938.60M 561.50M 572.90M 411.70M
Cash 1548.00M 10436.40M 1808.80M 1194.40M 657.80M
Cash and equivalents - - - - -
Total current liabilities 4608.00M 7108.20M 3103.60M 2141.50M 2188.20M
Current deferred revenue -2954.30320M -7415.37440M 2057.10M 1477.70M 1342.20M
Net debt 10679.00M -778.60000M 3998.10M 4798.40M 4005.00M
Short term debt 1055.00M 4494.00M 473.80M 202.30M 420.60M
Short long term debt 964.00M 4420.50M 396.00M 180.68M 595.32M
Short long term debt total 12227.00M 9657.80M 5806.90M 5992.80M 4662.80M
Other stockholder equity -29492.00020M -26783.81280M -16340.20072M -15580.08270M -18294.76012M
Property plant equipment 9352.00M 8308.60M 7536.00M 6305.40M 4484.30M
Total current assets 9259.00M 16460.70M 7389.70M 6446.20M 5540.10M
Long term investments 173.00M 402.90M 21.50M 20.69M 14.12M
Net tangible assets -660.00000M 11939.40M 5711.60M 4236.60M 3373.00M
Short term investments - - 4.80M 3.30M 0.40M
Net receivables 1905.00M 1483.20M 1563.70M 1558.20M 1704.90M
Long term debt 9564.00M 3862.50M 4228.50M 8426.93M 6021.25M
Inventory 5466.00M 4333.00M 3780.60M 3509.50M 3038.80M
Accounts payable 820.00M 591.80M 523.00M 458.30M 422.60M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 648.00M 590.30M 633.20M 336.30M 242.00M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 102.00M 18.20M 10.50M 15.60M 23.10M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 26975.00M 11885.30M 10767.20M 9018.40M 6774.30M
Capital lease obligations 1699.00M 1374.80M 1182.40M 124.44M 32.23M
Long term debt total - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -11843.00000M -387.70000M -387.70000M -387.70000M -387.70000M
Change to liabilities 197.00M 212.30M 454.90M 158.40M 136.20M
Total cashflows from investing activities -11843.00000M -1636.10000M -1673.20000M -1366.70000M -1287.30000M
Net borrowings 1661.00M 3723.70M -496.70000M 198.80M 288.30M
Total cash from financing activities 456.00M 7675.90M -1401.80000M -642.70000M -491.50000M
Change to operating activities 51.00M -102.70000M 56.40M -24.10000M 18.60M
Net income 3294.07M 3266.14M 3167.30M 3046.52M 2733.00M
Change in cash -8825.00000M 8604.30M 578.80M 493.50M -154.90000M
Begin period cash flow 10334.00M 1730.10M 1151.30M 657.80M 812.70M
End period cash flow 1509.00M 10334.40M 1730.10M 1151.30M 657.80M
Total cash from operating activities 3905.14M 3807.84M 4830.17M 3605.55M 2342.28M
Issuance of capital stock 34.00M 4988.40M 56.40M 42.00M 31.80M
Depreciation 1088.52M 647.43M 533.84M 508.60M 442.13M
Other cashflows from investing activities - -0.70000M -6.10000M 18.70M -2.50000M
Dividends paid -1239.00000M -1038.70000M -958.00000M -883.10000M 806.80M
Change to inventory -1361.76980M -1306.45680M -490.36472M -993.14460M -795.24252M
Change to account receivables 42.04M -65.17800M 48.68M 191.12M -522.89724M
Sale purchase of stock 2539.00M 4092.70M 38.70M 1652.70M 898.50M
Other cashflows from financing activities -80.00000M -50.10000M -68.00000M -55.10000M -4.80000M
Change to netincome 207.00M 668.80M 571.50M 385.20M 120.80M
Capital expenditures 1692.00M 1247.70M 1667.10M 1367.60M 1284.80M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -1319.73060M -1371.63480M -441.68832M -802.02150M -1318.13976M
Stock based compensation 208.69M 169.46M 122.42M 117.37M 74.07M
Other non cash items -477.44520M -105.73320M 1129.03M 50.43M -832.84668M
Free cash flow 2213.14M 2560.14M 3163.07M 2237.95M 1057.48M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSLLY
CSL Ltd		 0.10 0.42% 25.31 42.45 26.95 7.05 5.80 7.85 26.51
NVO
Novo Nordisk A/S		 0.11 0.28% 38.83 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -6.79 1.36% 492.38 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.63 0.34% 774.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Ltd

45 Poplar Road, Parkville, VIC, Australia, 3052

Key Executives

Name Title Year Born
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
Dr. Paul F. McKenzie Ph.D. Chief Operating Officer 1966
Mr. Mark Dehring Head of Investor Relations NA
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
Christina Hickie Sr. Mang. of Communications NA
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.